Arsenic Trioxide Phebra

Arsenic Trioxide Phebra contains arsenic trioxide 10 mg, sodium hydroxide, hydrochloric acid for pH adjustment, and water for injections to 10 ml.

Indication:
Arsenic Trioxide Phebra is indicated for induction of remission, and consolidation in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (ATRA) or patients with relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.